Peregrine Pharmaceuticals Inc (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

PPHM News and Commentary

Caps

How do you think PPHM will perform against the market?

Add Stock to CAPS Watchlist

All Players

119 Outperform
25 Underperform
 

All-Star Players

8 Outperform
12 Underperform
 

Wall Street

2 Outperform
1 Underperform
 

Top PPHM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ssanaka (< 20)
Submitted March 20, 2012

good product pipeline

AjarnMichael (82.28)
Submitted May 10, 2010

F

PPHM VS S&P 500 (SPY)

Fools bullish on PPHM are also bullish on:

Fools bearish on PPHM are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about PPHM.

Recs

0
Member Avatar DigitalDisco (90.54) Submitted: 7/10/2017 11:37:33 AM : Underperform Start Price: $4.32 PPHM Score: +15.63

reverse split

Recs

0
Member Avatar stetsonline (< 20) Submitted: 5/15/2015 12:32:27 PM : Outperform Start Price: $9.35 PPHM Score: -84.38

Bavituximab, Peregrine's novel therapeutic antibody has the potential to be used as a stand-alone or combination therapy to combat cancer and infectious diseases. Its MOA is unique in that it turns off the cloaking device diseases use to fool the immune system. There are numerous pre-clinical and early stage studies confirming its safety and efficacy. A pivotal trial look-in or partnering event is likely to happen in the next 6-12 months.

Recs

0
Member Avatar Lz (< 20) Submitted: 2/13/2015 11:28:21 AM : Outperform Start Price: $8.89 PPHM Score: -83.70

1. one year into phase III sunset trials for lung cancer at over 150 sites world wide.
2. New data shows that their leading drug Bavi significantly enhance anti- tumor activity in both breast cancer and melanoma.
3. phase II using Bavi with Sorafenib showed patients with prolonged survival warranting further clinical evaluation of this combination in later stage clinical trials
4. Bavituximab pipeline: phase III NSLC second line, phase II liver cancer, phase I Her2-neg breast, phase 1 advanced melanoma; Tumor imaging: in phase one
5. Avid bioservices, Peregrine's subsidiary, which provides a range of biomanufacturing services and manufactures clinical products, is expanding - confirmed with glassdoor job opportunities posted.

Leaderboard

Find the members with the highest scoring picks in PPHM.

Score Leader

zzlangerhans

zzlangerhans (99.55) Score: +437.64

Got to love those 50 cent picks.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
AjarnMichael 82.28 5/10/2010 Underperform 5Y $26.04 -83.79% +137.23% +221.03 2 Comments
octoberfast 97.00 10/15/2010 Underperform 5Y $11.48 -63.24% +132.28% +195.52 0 Comment
c0stroks 66.32 11/1/2010 Underperform 3M $10.57 -60.08% +130.74% +190.81 0 Comment
golfsd27 < 20 8/16/2011 Underperform 3M $10.14 -58.39% +129.00% +187.39 0 Comment
Kdesert 29.38 9/4/2012 Underperform 5Y $19.18 -78.00% +94.80% +172.79 0 Comment
Smallcappy < 20 8/14/2012 Underperform 3W $18.48 -77.16% +95.02% +172.18 1 Comment
BlacknGold2 60.42 8/29/2012 Underperform 5Y $17.08 -75.29% +94.44% +169.73 0 Comment
resistanceps3 < 20 1/7/2013 Underperform 5Y $16.63 -74.62% +88.22% +162.83 0 Comment
setonhall 69.99 1/7/2013 Underperform 3W $15.89 -73.44% +88.75% +162.19 0 Comment
headyinvestor 68.23 9/24/2012 Underperform 5Y $7.28 -42.03% +89.15% +131.18 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 87.40 3/8/2013 Outperform NS $10.29 -58.99% +76.73% -135.72 0 Comment
TrackRothCapital 76.50 8/16/2012 Outperform NS $19.25 -53.09% +3.39% -56.48 9/25/2012 @ $9.03 0 Comment
TrackPoisedTo < 20 8/14/2012 Underperform 5Y $21.42 -80.30% +94.45% +174.75 0 Comment
TrackJMP 85.03 8/30/2011 Outperform NS $10.15 -58.42% +127.91% -186.33 0 Comment

Featured Broker Partners


Advertisement